Literature DB >> 19423571

Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.

Yi-Wen Chiu1, Isaac Teitelbaum, Madhukar Misra, Essel Marie de Leon, Tochi Adzize, Rajnish Mehrotra.   

Abstract

BACKGROUND AND OBJECTIVES: Dialysis patients have a high burden of co-existing diseases, poor health-related quality of life (HR-QOL), and are prescribed many medications. There are no data on daily pill burden and its relationship to HR-QOL and adherence to therapy. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Two hundred and thirty-three prevalent, chronic dialysis patients from three units in different geographic areas in the United States underwent a single, cross-sectional assessment of total daily pill burden and that from phosphate binders. HR-QOL, adherence to phosphate binders, and serum phosphorus levels were the three main outcome measures studied.
RESULTS: The median daily pill burden was 19; in one-quarter of subjects, it exceeded 25 pills/d. Higher pill burden was independently associated with lower physical component summary scale scores on HR-QOL on both univariate and multivariate analyses. Phosphate binders accounted for about one-half of the daily pill burden; 62% of the participants were nonadherent. There was a modest relationship between pill burden from phosphate binders and adherence and serum phosphorus levels; these associations persisted on multivariate analyses. There was no relationship between adherence and serum phosphorus levels.
CONCLUSIONS: The daily pill burden in dialysis patients is one of the highest reported to date in any chronic disease state. Higher pill burden is associated with lower HR-QOL. There are many reasons for uncontrolled serum phosphorus levels; increasing the number of prescribed pills does not seem to improve control and may come at the cost of poorer HR-QOL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19423571      PMCID: PMC2689877          DOI: 10.2215/CJN.00290109

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  21 in total

1.  Serum phosphate levels and mortality risk among people with chronic kidney disease.

Authors:  Bryan Kestenbaum; Joshua N Sampson; Kyle D Rudser; Donald J Patterson; Stephen L Seliger; Bessie Young; Donald J Sherrard; Dennis L Andress
Journal:  J Am Soc Nephrol       Date:  2004-12-22       Impact factor: 10.121

2.  The USRDS Dialysis Morbidity and Mortality Study: Wave 2. United States Renal Data System.

Authors: 
Journal:  Am J Kidney Dis       Date:  1997-08       Impact factor: 8.860

3.  The association between mental health, physical function, and hemodialysis mortality.

Authors:  Eric L Knight; Norma Ofsthun; Ming Teng; J Michael Lazarus; Gary C Curhan
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

4.  Medical outcomes study short form-36: a consistent and powerful predictor of morbidity and mortality in dialysis patients.

Authors:  Edmund G Lowrie; Roberta Braun Curtin; Nancy LePain; Dorian Schatell
Journal:  Am J Kidney Dis       Date:  2003-06       Impact factor: 8.860

5.  Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Donna L Mapes; Antonio Alberto Lopes; Sudtida Satayathum; Keith P McCullough; David A Goodkin; Francesco Locatelli; Shunichi Fukuhara; Eric W Young; Kiyoshi Kurokawa; Akira Saito; Jürgen Bommer; Robert A Wolfe; Philip J Held; Friedrich K Port
Journal:  Kidney Int       Date:  2003-07       Impact factor: 10.612

6.  Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.

Authors:  Rajnish Mehrotra; Kevin J Martin; Steven Fishbane; Stuart M Sprague; Steven Zeig; Michael Anger
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 8.237

7.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Authors:  Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

8.  Development of the kidney disease quality of life (KDQOL) instrument.

Authors:  R D Hays; J D Kallich; D L Mapes; S J Coons; W B Carter
Journal:  Qual Life Res       Date:  1994-10       Impact factor: 4.147

9.  Medication prescribing patterns in ambulatory haemodialysis patients: comparisons of USRDS to a large not-for-profit dialysis provider.

Authors:  Harold J Manley; Cory G Garvin; Debra K Drayer; Gerald M Reid; Walter L Bender; Timothy K Neufeld; Sudarshan Hebbar; Richard S Muther
Journal:  Nephrol Dial Transplant       Date:  2004-05-05       Impact factor: 5.992

10.  The quality of life of patients with end-stage renal disease.

Authors:  R W Evans; D L Manninen; L P Garrison; L G Hart; C R Blagg; R A Gutman; A R Hull; E G Lowrie
Journal:  N Engl J Med       Date:  1985-02-28       Impact factor: 91.245

View more
  193 in total

1.  Patterns and predictors of depression treatment among adults with chronic kidney disease and depression in ambulatory care settings in the United States.

Authors:  Nina Vadiei; Sandipan Bhattacharjee
Journal:  Int Urol Nephrol       Date:  2018-12-04       Impact factor: 2.370

Review 2.  Association between medication regimen complexity and pharmacotherapy adherence: a systematic review.

Authors:  Laís Lessa Pantuzza; Maria das Graças Braga Ceccato; Micheline Rosa Silveira; Luane Mendes Ribeiro Junqueira; Adriano Max Moreira Reis
Journal:  Eur J Clin Pharmacol       Date:  2017-08-04       Impact factor: 2.953

3.  Medication adherence in Greek hemodialysis patients: the contribution of depression and health cognitions.

Authors:  Paraskevi Theofilou
Journal:  Int J Behav Med       Date:  2013-06

4.  Effects of frequent hemodialysis on measures of CKD mineral and bone disorder.

Authors:  John T Daugirdas; Glenn M Chertow; Brett Larive; Andreas Pierratos; Tom Greene; Juan Carlos Ayus; Cynthia A Kendrick; Sam H James; Brent W Miller; Gerald Schulman; Isidro B Salusky; Alan S Kliger
Journal:  J Am Soc Nephrol       Date:  2012-02-23       Impact factor: 10.121

5.  Sources of drug coverage among Medicare beneficiaries with ESRD.

Authors:  Benjamin L Howell; Christopher A Powers; Eric D Weinhandl; Wendy L St Peter; Diane L Frankenfield
Journal:  J Am Soc Nephrol       Date:  2012-03-08       Impact factor: 10.121

6.  A wearable artificial kidney for patients with end-stage renal disease.

Authors:  Victor Gura; Matthew B Rivara; Scott Bieber; Raj Munshi; Nancy Colobong Smith; Lori Linke; John Kundzins; Masoud Beizai; Carlos Ezon; Larry Kessler; Jonathan Himmelfarb
Journal:  JCI Insight       Date:  2016-06-02

7.  Medication reconciliation and therapy management in dialysis-dependent patients: need for a systematic approach.

Authors:  Amy Barton Pai; Katie E Cardone; Harold J Manley; Wendy L St Peter; Rachel Shaffer; Michael Somers; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 8.237

8.  Renal pharmacists' perceptions and current practices of assessing medication adherence in dialysis patients.

Authors:  Saurav Ghimire; Colin Banks; Matthew D Jose; Ronald L Castelino; Syed Tabish R Zaidi
Journal:  Int J Clin Pharm       Date:  2017-12-06

9.  MgCaCO3 versus CaCO3 in peritoneal dialysis patients--a cross-over pilot trial.

Authors:  Baigalmaa Evsanaa; Irene Liu; Babak Aliazardeh; Sara Mahdavi; Gursarn Bajwa; Jerry Gula; Michelle Tam; Elena Sze; Janet M Roscoe; Paul Y Tam; Tabo Sikaneta
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

Review 10.  Sucroferric oxyhydroxide: a review in hyperphosphataemia in chronic kidney disease patients undergoing dialysis.

Authors:  Sarah L Greig; Greg L Plosker
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.